Refining patient selection for neoadjuvant chemotherapy before radical cystectomy

Journal of Urology

Volumn 191, Issue 1, 2014, Pages 40-47

  Culp, Stephen H ^a   Dickstein, Rian J ^b   Grossman, H Barton ^b   Pretzsch, Shanna M ^b   Porten, Sima ^b   Daneshmand, Siamak ^d   Cai, Jie ^d   Groshen, Susan ^d   Siefker Radtke, Arlene ^c   Millikan, Randall E ^c   Czerniak, Bogdan ^b   Navai, Neema ^b   Wszolek, Matthew F ^b   Kamat, Ashish M ^b   Dinney, Colin P N ^b  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

cystectomy; neoadjuvant therapy; outcomes assessment; risk; urinary bladder neoplasms

Indexed keywords

ANTINEOPLASTIC AGENT; HEMOGLOBIN;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURGERY; COHORT ANALYSIS; COMPARATIVE STUDY; CYSTECTOMY; DISEASE SPECIFIC SURVIVAL; FEMALE; HIGH RISK PATIENT; HISTOLOGY; HUMAN; HUMAN TISSUE; HYDROURETER; LOW RISK POPULATION; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MALE; MUSCLE INVASIVE BLADDER CANCER; OVERALL SURVIVAL; PATIENT SELECTION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SURVIVAL RATE; TRANSURETHRAL RESECTION; ADJUVANT THERAPY; CANCER RISK; CANCER SURVIVAL; COMORBIDITY; CONTROLLED STUDY; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; LOW RISK PATIENT; MULTIMODALITY CANCER THERAPY; PATIENT IDENTIFICATION;

3-D; 3-DIMENSIONAL; BC; BLADDER CANCER; CAUSE SPECIFIC MORTALITY; CSM; CYSTECTOMY; DISEASE SPECIFIC SURVIVAL; DSS; EUA; EXAMINATION UNDER ANESTHESIA; HIGH RISK; HR; LOW RISK; LR; LVI; LYMPHOVASCULAR INVASION; MDACC; MIBC; MUSCLE INVASIVE BLADDER CANCER; NAC; NEOADJUVANT CHEMOTHERAPY; NEOADJUVANT THERAPY; OS; OUTCOMES ASSESSMENT; OVERALL SURVIVAL; PFS; PROGRESSION-FREE SURVIVAL; RADICAL CYSTECTOMY; RC; RISK; TRANSURETHRAL RESECTION; TUR; UNIVERSITY OF SOUTHERN CALIFORNIA; UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER; URINARY BLADDER NEOPLASMS; USC; VARIANT HISTOLOGY; VH;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, TRANSITIONAL CELL; CYSTECTOMY; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PATIENT SELECTION; SURVIVAL ANALYSIS; URINARY BLADDER NEOPLASMS;

EID: 84890127566     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2013.07.061     Document Type: Article

References (29)

1. J.P. Stein, G. Lieskovsky, and R. Cote Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients J Clin Oncol 19 2001 666
2. R.E. Hautmann, J.E. Gschwend, and R.C. de Petriconi Cystectomy for transitional cell carcinoma of the bladder: results of a surgery only series in the neobladder era J Urol 176 2006 486
3. H.B. Grossman, R.B. Natale, and C.M. Tangen Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer N Engl J Med 349 2003 859
4. Advanced Bladder Cancer Meta-analysis Collaboration Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis Lancet 361 2003 1927
5. E. Winquist, T.S. Kirchner, and R. Segal Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis J Urol 171 2004 561
6. C.J. Logothetis, D.E. Johnson, and C. Chong Adjuvant cyclophosphamide, doxorubicin, and cisplatin chemotherapy for bladder cancer: an update J Clin Oncol 6 1988 1590
7. Edge SB, Boyd DR, Compton CC, et al. Urinary bladder. In: AJCC Cancer Staging Manual, 7th ed. New York: Springer, 2010; part IX, pp 497-506.
8. R. Millikan, A. Siefker-Radtke, and H.B. Grossman Neoadjuvant chemotherapy for bladder cancer Urol Oncol 21 2003 464
9. K.I. Wishnow, A.K. Levinson, and D.E. Johnson Stage B (P2/3A/N0) transitional cell carcinoma of bladder highly curable by radical cystectomy Urology 39 1992 12
10. J.P. Fine, and R.J. Gray A proportional hazards model for the subdistribution of a competing risk J Am Stat Assoc 94 1999 496
11. G.V. Raj, S. Karavadia, and B. Schlomer Contemporary use of perioperative cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer Cancer 117 2011 276
12. B.S. Chang, H.L. Kim, and X.J. Yang Correlation between biopsy and radical cystectomy in assessing grade and depth of invasion in bladder urothelial carcinoma Urology 57 2001 1063
13. V. Ficarra, O. Dalpiaz, and N. Alrabi Correlation between clinical and pathological staging in a series of radical cystectomies for bladder carcinoma BJU Int 95 2005 786
14. B.K. Hollenbeck, D.C. Miller, and R.L. Dunn The effects of stage divergence on survival after radical cystectomy for urothelial cancer Urol Oncol 23 2005 77
15. S. McLaughlin, J. Shephard, and E. Wallen Comparison of the clinical and pathologic staging in patients undergoing radical cystectomy for bladder cancer Int Braz J Urol 33 2007 25
16. R. Millikan, C. Dinney, and D. Swanson Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC J Clin Oncol 19 2001 4005
17. S.F. Shariat, G.S. Palapattu, and P.I. Karakiewicz Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy Eur Urol 51 2007 137
18. D. Canter, C. Long, and A. Kutikov Clinicopathological outcomes after radical cystectomy for clinical T2 urothelial carcinoma: further evidence to support the use of neoadjuvant chemotherapy BJU Int 107 2011 58
19. A.B. Apolo, I. Ostrovnaya, and S. Halabi Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy J Natl Cancer Inst 105 2013 499
20. Y. Lotan, A. Gupta, and S.F. Shariat Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy J Clin Oncol 23 2005 6533
21. N.M. Streeper, C.M. Simons, and B.R. Konety The significance of lymphovascular invasion in transurethral resection of bladder tumour and cystectomy specimens on the survival of patients with urothelial bladder cancer BJU Int 103 2009 475
22. D. Canter, T. Guzzo, and M. Resnick The presence of lymphovascular invasion in radical cystectomy specimens from patients with urothelial carcinoma portends a poor clinical prognosis BJU Int 102 2008 952
23. A.M. Kamat, C.P. Dinney, and J.R. Gee Micropapillary bladder cancer: a review of the University of Texas M. D. Anderson Cancer Center experience with 100 consecutive patients Cancer 110 2007 62
24. C.J. Stimson, M.S. Cookson, and D.A. Barocas Preoperative hydronephrosis predicts extravesical and node positive disease in patients undergoing cystectomy for bladder cancer J Urol 183 2010 1732
25. D.M. Chapman, K.S. Pohar, and M.C. Gong Preoperative hydronephrosis as an indicator of survival after radical cystectomy Urol Oncol 27 2009 491
26. C.G. Rogers, G.S. Palapattu, and S.F. Shariat Clinical outcomes following radical cystectomy for primary nontransitional cell carcinoma of the bladder compared to transitional cell carcinoma of the bladder J Urol 175 2006 2048
27. A.O. Siefker-Radtke, C.P. Dinney, and N.A. Abrahams Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: a retrospective review of the M. D. Anderson cancer experience J Urol 172 2004 481
28. S.P. Lynch, Y. Shen, and A. Kamat Neoadjuvant chemotherapy in small cell urothelial cancer improves pathologic downstaging and long-term outcomes: results from a retrospective study at the MD Anderson Cancer Center Eur Urol 64 2013 307
29. A.O. Siefker-Radtke, A.M. Kamat, and H.B. Grossman Phase II clinical trial of neoadjuvant alternating doublet chemotherapy with ifosfamide/ doxorubicin and etoposide/cisplatin in small-cell urothelial cancer J Clin Oncol 27 2009 2592